Sweden-based medical device company Integrum AB (Nasdaq First North Growth Market: INTEG B) announced on Monday that it has conducted a pre-submission meeting with the US Food and Drug Administration (FDA) to discuss regulatory pathways for the OPRA Implant System in transhumeral (above elbow) amputations.
Following this meeting, Integrum intends to submit a Pre-Market Approval (PMA) application based on existing clinical data.
Having secured PMA for transfemoral (above-knee) amputations in December 2020, Integrum aims to expand regulatory approval to include transhumeral amputations in the US. Following a recent FDA meeting and internal analysis, Integrum believes existing clinical data may suffice for PMA qualification. The company plans to submit the application in the first half of 2024.
SHL Telemedicine introduces SmartHeart direct-to-consumer membership plan
Broncus Hangzhou signs Equity Transfer Agreement with Hangzhou Jingliang shareholders
Bracco signs long-term partnership with ulrich GmbH
L&T Technology Services plans to revolutionise medical imaging in collaboration with NVIDIA
Eli Lilly to build new high-tech manufacturing site in Germany
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Zymo Research's SafeCollect Saliva Collection Kit receives US FDA approval
Kanabo Group extends contract with major UK retailer
Biodesix enhances Nodify Lung testing with Tasso+ blood draw method
Byotrol unveils PROCESSUS instrument decontamination system
Integrum plans FDA PMA submission for OPRA in transhumeral amputations
Telix and Mauna Kea Technologies expand collaboration in urologic oncology surgery
Egetis secures exclusive licence agreement with Fujimoto for Emcitate development in Japan
KDx Diagnostics enters into strategic collaborations with leading distributors in Europe